< Back to previous page
Patent
MCL-1 AS CRITICAL REGULATOR OF FOXP3+ REGULATORY T CELL SURVIVAL, AND USE THEREOF TO TREAT SEVERE IMMUNE DISORDERS
The present application relates to the field of immunology, more particularly to diseases and disorders characterized by insufficient numbers of Foxp3 positive regulatory T cells (Tregs). The mechanisms of the homeostatic processes that regulate the Treg numbers were studied, and it was found that Mcl-expression is critical for Treg survival. As most studies aiming at increasing Treg numbers to modulate immunity only achieve a transient increase, this finding has important therapeutic consequences: combined Mcl-1 and Foxp3 expression results in a stable population of Treg cells; enhancing Treg numbers will result in clinical improvement in many severe immune disorders.
Patent Publication Number: WO2014180943
Year filing: 2014
Year approval: 2015
Year publication: 2014
Status: Requested
URI: link to Espacenet
Technology domains: Pharmaceuticals
Validated for IOF-key: Yes
Attributed to: Associatie KULeuven